Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
| Revenue (Most Recent Fiscal Year) | $1.00M |
| Net Income (Most Recent Fiscal Year) | $-130.93M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -15079.90% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -130.53% |
| Return on Assets (Trailing 12 Months) | -66.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.57 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.57 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.25 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.40 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 20.89M |
| Free Float | 19.64M |
| Market Capitalization | $47.63M |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | 0.70 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 48.17% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |